{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:07:51Z","timestamp":1787828871852,"version":"build-2784847793"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Shanghai Municipal Health Planning Commission","award":["2018YQ48"],"award-info":[{"award-number":["2018YQ48"]}]},{"name":"The Drug Innovation Major Project","award":["2018ZX09734005-001-002"],"award-info":[{"award-number":["2018ZX09734005-001-002"]}]},{"name":"The Drug Innovation Major Project","award":["2018ZX09734005-006"],"award-info":[{"award-number":["2018ZX09734005-006"]}]},{"name":"The Drug Innovation Major Project","award":["2018ZX09711001-009-001"],"award-info":[{"award-number":["2018ZX09711001-009-001"]}]},{"name":"The Drug Innovation Major Project","award":["2018ZX09731016"],"award-info":[{"award-number":["2018ZX09731016"]}]},{"name":"The Drug Innovation Major Project","award":["2017ZX09304003"],"award-info":[{"award-number":["2017ZX09304003"]}]},{"name":"Science and Technology Innovation Action Plan of Shanghai","award":["17401970900"],"award-info":[{"award-number":["17401970900"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Model-based meta-analysis was used to describe the time-course and dose-effect relationships of antidepressants and also simultaneously investigate the impact of various factors on drug efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study is a reanalysis of a published network meta-analysis. Only placebo-controlled trials were included in this study. The change rate in depression rating scale scores from baseline was used as an efficacy indicator because a continuous variable is more likely to reflect subtle differences in efficacy between drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total 230 studies containing 64\u2009346 patients were included in the analysis. The results showed that the number of study sites (single or multi-center) and the type of setting (inpatient or noninpatient) are important factors affecting the efficacy of antidepressants. After deducting the placebo effect, the maximum pure drug efficacy value of inpatients was 18.4% higher than that of noninpatients, and maximum pure drug efficacy value of single-center trials was 10.2% higher than that of multi-central trials. Amitriptyline showed the highest drug efficacy. The remaining 18 antidepressants were comparable or had little difference. Within the approved dose range, no significant dose-response relationship was observed. However, the time-course relationship is obvious for all antidepressants. In terms of safety, with the exception of amitriptyline, the dropout rate due to adverse events of other drugs was not more than 10% higher than that of the placebo group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The number of study sites and the type of setting are significant impact factors for the efficacy of antidepressants. Except for amitriptyline, the other 18 antidepressants have little difference in efficacy and safety.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ijnp\/pyz062","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T12:11:33Z","timestamp":1574770293000},"page":"76-87","source":"Crossref","is-referenced-by-count":35,"title":["Analysis of Time-Course, Dose-Effect, and Influencing Factors of Antidepressants in the Treatment of Acute Adult Patients With Major Depression"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5351-7538","authenticated-orcid":false,"given":"Qingqing","family":"Cheng","sequence":"first","affiliation":[{"name":"Center for Drug of Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihan","family":"Huang","sequence":"first","affiliation":[{"name":"Center for Drug of Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Xu","sequence":"first","affiliation":[{"name":"Center for Drug of Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Li","sequence":"first","affiliation":[{"name":"Center for Drug of Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafang","family":"Li","sequence":"first","affiliation":[{"name":"Shanghai Mental Health Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Shen","sequence":"first","affiliation":[{"name":"Shanghai Mental Health Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Zheng","sequence":"first","affiliation":[{"name":"Center for Drug of Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujin","family":"Li","sequence":"first","affiliation":[{"name":"Center for Drug of Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,27]]},"reference":[{"key":"2020032608374853800_CIT0001","doi-asserted-by":"crossref","first-page":"h6019","DOI":"10.1136\/bmj.h6019","article-title":"Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis","volume":"351","author":"Amick","year":"2015","journal-title":"Bmj"},{"key":"2020032608374853800_CIT0002","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.xphs.2017.02.001","article-title":"Population pharmacokinetics of darbepoetin in infants following single intravenous and subcutaneous dosing","volume":"106","author":"An","year":"2017","journal-title":"J Pharm Sci"},{"key":"2020032608374853800_CIT0003","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF00444686","article-title":"Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients","volume":"98","author":"Ansseaul","year":"1989","journal-title":"Psychopharmacology"},{"key":"2020032608374853800_CIT0004","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3109\/15622975.2013.804195","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders","volume":"14","author":"Bauer","year":"2013","journal-title":"World J Biol Psychiatry"},{"key":"2020032608374853800_CIT0006","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ijnp\/pyx070","article-title":"A Network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder","volume":"21","author":"Baune","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"2020032608374853800_CIT0007","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.sleep.2003.08.007","article-title":"Trazodone as a hypnotic in major depression","volume":"5","author":"Becker","year":"2004","journal-title":"Sleep Med"},{"key":"2020032608374853800_CIT0008","doi-asserted-by":"crossref","first-page":"249","DOI":"10.31887\/DCNS.2005.7.3\/pberney","article-title":"Dose-response relationship of recent antidepressants in the short-term treatment of depression","volume":"7","author":"Berney","year":"2005","journal-title":"Dialogues Clin Neurosci"},{"key":"2020032608374853800_CIT0009","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/psp4.12041","article-title":"The many flavors of model-based meta-analysis: part I-introduction and landmark data","volume":"5","author":"Boucher","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2020032608374853800_CIT0010","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"key":"2020032608374853800_CIT0011","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"2020032608374853800_CIT0012","first-page":"151","article-title":"Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder","volume":"18","author":"Clayton","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"2020032608374853800_CIT0013","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881115581093","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines","volume":"29","author":"Cleare","year":"2015","journal-title":"J Psychopharmacol"},{"key":"2020032608374853800_CIT0014","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1517\/14656566.2014.960842","article-title":"A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine","volume":"15","author":"Deardorff","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"2020032608374853800_CIT0016","doi-asserted-by":"crossref","first-page":"e010919","DOI":"10.1136\/bmjopen-2015-010919","article-title":"Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis","volume":"6","author":"Furukawa","year":"2016","journal-title":"BMJ Open"},{"key":"2020032608374853800_CIT0017","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S2215-0366(19)30217-2","article-title":"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis","volume":"6","author":"Furukawa","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"2020032608374853800_CIT0018","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S2215-0366(19)30339-6","article-title":"Optimal dosing of antidepressant drugs - authors\u2019 reply","volume":"6","author":"Furukawa","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"2020032608374853800_CIT0021","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1038\/tp.2016.104","article-title":"A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors","volume":"6","author":"Hieronymus","year":"2016","journal-title":"Transl Psychiatry"},{"key":"2020032608374853800_CIT0022","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1747-5341-3-14","article-title":"Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?","volume":"3","author":"Ioannidis","year":"2008","journal-title":"Philos Ethics Humanit Med"},{"key":"2020032608374853800_CIT0023","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12888-017-1311-5","article-title":"Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and trial sequential analysis","volume":"17","author":"Jakobsen","year":"2017","journal-title":"BMC Psychiatry"},{"key":"2020032608374853800_CIT0024","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1176\/appi.ajp.2016.16030304r","article-title":"Addressing difficulties in the study of dose-response relationships of SSRIs in depression: response to Hieronymus and Eriksson","volume":"173","author":"Jakubovski","year":"2016","journal-title":"Am J Psychiatry"},{"key":"2020032608374853800_CIT0025","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1176\/appi.ajp.2015.15030331","article-title":"Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder","volume":"173","author":"Jakubovski","year":"2016","journal-title":"Am J Psychiatry"},{"key":"2020032608374853800_CIT0026","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.euroneuro.2005.09.002","article-title":"Placebo-controlled trial of agomelatine in the treatment of major depressive disorder","volume":"16","author":"Kennedy","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"key":"2020032608374853800_CIT0027","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40263-015-0267-6","article-title":"Network meta-analysis and cost-effectiveness analysis of new generation antidepressants","volume":"29","author":"Khoo","year":"2015","journal-title":"CNS Drugs"},{"key":"2020032608374853800_CIT0028","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.clpt.6100235","article-title":"Model-based drug development","volume":"82","author":"Lalonde","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"2020032608374853800_CIT0029","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1472-6963-13-173","article-title":"Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece","volume":"13","author":"Maniadakis","year":"2013","journal-title":"BMC Health Serv Res"},{"key":"2020032608374853800_CIT0030","doi-asserted-by":"crossref","first-page":"e024886","DOI":"10.1136\/bmjopen-2018-024886","article-title":"Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis","volume":"9","author":"Munkholm","year":"2019","journal-title":"BMJ Open"},{"key":"2020032608374853800_CIT0031","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12161","article-title":"Model evaluation of continuous data pharmacometric models: metrics and graphics","volume":"6","author":"Nguyen","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2020032608374853800_CIT0032","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/14656566.2019.1574747","article-title":"Agomelatine for depression: expanding the horizons?","volume":"20","author":"Norman","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"2020032608374853800_CIT0033","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/03007995.2016.1277201","article-title":"Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis","volume":"33","author":"Papadimitropoulou","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"2020032608374853800_CIT0034","doi-asserted-by":"crossref","first-page":"350","DOI":"10.7326\/M15-2570","article-title":"Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians","volume":"164","author":"Qaseem","year":"2016","journal-title":"Ann Intern Med"},{"key":"2020032608374853800_CIT0036","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1176\/appi.ajp.2012.12040474","article-title":"A model of placebo response in antidepressant clinical trials","volume":"170","author":"Rutherford","year":"2013","journal-title":"Am J Psychiatry"},{"key":"2020032608374853800_CIT0037","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000209348","article-title":"Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials","volume":"78","author":"Rutherford","year":"2009","journal-title":"Psychother Psychosom"},{"key":"2020032608374853800_CIT0038","doi-asserted-by":"crossref","first-page":"212290","DOI":"10.7573\/dic.212290","article-title":"Antidepressant efficacy and side-effect burden: a quick guide for clinicians","volume":"4","author":"Santarsieri","year":"2015","journal-title":"Drugs Context"},{"key":"2020032608374853800_CIT0040","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1081\/CBI-100107514","article-title":"S20098 affects the free-running rhythms of body temperature and activity and decreases light-induced phase delays of circadian rhythms of the rat","volume":"18","author":"Tuma","year":"2001","journal-title":"Chronobiol Int"},{"key":"2020032608374853800_CIT0041","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/npp.2011.306","article-title":"Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review","volume":"37","author":"Undurraga","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"2020032608374853800_CIT0042","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jpsychires.2017.07.003","article-title":"Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with major depressive disorder: systematic review and meta-analysis","volume":"94","author":"Wagner","year":"2017","journal-title":"J Psychiatr Res"},{"key":"2020032608374853800_CIT0043","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.287.14.1840","article-title":"Placebo response in studies of major depression: variable, substantial, and growing","volume":"287","author":"Walsh","year":"2002","journal-title":"Jama"},{"key":"2020032608374853800_CIT0044","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4068\/cmj.2016.52.3.159","article-title":"Second generation antipsychotics in the treatment of major depressive disorder: an update","volume":"52","author":"Wang","year":"2016","journal-title":"Chonnam Med J"},{"key":"2020032608374853800_CIT0045","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3346\/jkms.2014.29.4.468","article-title":"Evidence-based, pharmacological treatment guideline for depression in Korea, revised edition","volume":"29","author":"Won","year":"2014","journal-title":"J Korean Med Sci"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyz062\/31798544\/pyz062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/23\/2\/76\/32967745\/pyz062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/23\/2\/76\/32967745\/pyz062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T15:26:44Z","timestamp":1612625204000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/23\/2\/76\/5644522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,27]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyz062","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2019,11,27]]}}}